View by Specialty

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

Therapeutics/Diagnostics News

SPONSORED CONTENT
January 16, 2025
3 min read
Save
IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s

IBD drug market rattles as Lilly’s Omvoh nabs FDA approval for second IL-23p19 in Crohn’s

The FDA has approved Omvoh for the treatment of moderately to severely active Crohn’s disease, making it the second interleukin-23p19 specific inhibitor approved for both major types of inflammatory bowel disease, Lilly reported.

SPONSORED CONTENT
January 14, 2025
2 min read
Save

Prucalopride still effective in CIC despite older age, unhealthy BMI or renal impairment

Prucalopride still effective in CIC despite older age, unhealthy BMI or renal impairment

Prucalopride was safe and effective in increasing the frequency of complete spontaneous bowel movements in patients with chronic idiopathic constipation, regardless of age, BMI or renal function, according to data.

SPONSORED CONTENT
January 08, 2025
2 min read
Save

Improved physician ADR from a baseline of less than 26% linked to lower CRC risk

Improved physician ADR from a baseline of less than 26% linked to lower CRC risk

Improvement in adenoma detection rate among physicians with a baseline rate of less than 26% was significantly associated with decreased patient risk for colorectal cancer, according to results of an observational study conducted in Poland.

Trending

PC0125Qi_Graphic_01_WEB
January 10, 2025
3 min read
Save

Drinking coffee in the morning reduces the risk for death

SPONSORED CONTENT
December 27, 2024
5 min read
Save

Can uptick in noninvasive CRC screening tests compete with standard colonoscopy?

Can uptick in noninvasive CRC screening tests compete with standard colonoscopy?

Newly available noninvasive colorectal cancer tests have opened the doors to an uptick in screening, especially the first FDA-approved blood test. However, experts are unsure whether these will be as effective as colonoscopy.

SPONSORED CONTENT
December 26, 2024
4 min read
Save

Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025

Biosimilar boom set to expand treatment landscape for IBD, inflammatory diseases in 2025

The expansion of safe and effective FDA-approved biosimilars for inflammatory bowel disease set to launch in early 2025 may improve access to care, with the potential to reduce health care costs and revolutionize the treatment landscape.

SPONSORED CONTENT
December 20, 2024
2 min read
Save

FDA approves Ionis’ Tryngolza as first treatment for familial chylomicronemia syndrome

FDA approves Ionis’ Tryngolza as first treatment for familial chylomicronemia syndrome

The FDA approved Tryngolza for the treatment of adults with familial chylomicronemia syndrome when used in combination with an appropriate low-fat diet, according to an Ionis Pharmaceutical press release.

SPONSORED CONTENT
December 04, 2024
2 min read
Save

AGA updates living guideline on pharmacological management of moderate to severe UC

AGA updates living guideline on pharmacological management of moderate to severe UC

In light of a “significant expansion in the therapeutic armamentarium” for moderate to severe ulcerative colitis, the AGA has released an updated living clinical practice guideline of patient-centered pharmacological interventions.

SPONSORED CONTENT
December 03, 2024
2 min read
Save

Concomitant use of common medications does not significantly affect UC induction therapy

Concomitant use of common medications does not significantly affect UC induction therapy

Baseline concomitant exposure to commonly used medications, such as corticosteroids and 5-aminosalicylates, did not significantly affect clinical and endoscopic outcomes during induction therapy in ulcerative colitis, data analysis showed.

SPONSORED CONTENT
November 15, 2024
5 min watch
Save

VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease

VIDEO: Subcutaneous guselkumab induction achieves clinical remission in Crohn’s disease

PHILADELPHIA — Subcutaneous guselkumab outperformed placebo and, as with IV administration, appears to have “profound induction effects” on both clinical remission and endoscopic response in Crohn’s disease, a presenter told Healio.

SPONSORED CONTENT
November 14, 2024
2 min read
Save

Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations

Pharmacotherapy for alcohol use disorder ‘underutilized’ in at-risk populations

PHILADELPHIA — Pharmacologic therapy for alcohol use disorder may be an “underutilized treatment modality,” especially in patients with related liver disease, according to research presented at the ACG Annual Scientific Meeting.

View more
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails
Healio Minute Subscribe to Healio Minute emails You're now subscribed to Healio Minute Emails